Aktis Oncology (NASDAQ:AKTS) Posts Quarterly Earnings Results, Hits Expectations

Aktis Oncology (NASDAQ:AKTS) announced its quarterly earnings data on Thursday. The technology company reported ($0.44) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.44), reports. The firm had revenue of $3.38 million during the quarter, compared to the consensus estimate of $2.14 million.

Aktis Oncology Trading Down 0.9%

Aktis Oncology stock traded down $0.21 during mid-day trading on Thursday, reaching $23.79. The company had a trading volume of 156,314 shares, compared to its average volume of 339,686. The business has a fifty day simple moving average of $24.79 and a 200 day simple moving average of $21.11. The company has a market cap of $1.27 billion and a P/E ratio of -62.61. Aktis Oncology has a fifty-two week low of $14.72 and a fifty-two week high of $34.19.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on AKTS. JPMorgan Chase & Co. raised their target price on Aktis Oncology from $30.00 to $33.00 and gave the company an “overweight” rating in a report on Tuesday, July 14th. Weiss Ratings raised Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, June 23rd. Wall Street Zen lowered Aktis Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, July 25th. Raymond James Financial assumed coverage on Aktis Oncology in a research report on Monday, June 15th. They issued a “strong-buy” rating and a $40.00 target price on the stock. Finally, William Blair assumed coverage on Aktis Oncology in a research note on Wednesday, April 29th. They set an “outperform” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Aktis Oncology has a consensus rating of “Moderate Buy” and a consensus price target of $34.60.

Insider Activity at Aktis Oncology

In related news, Director Ken Herrmann sold 4,856 shares of the firm’s stock in a transaction on Monday, July 20th. The stock was sold at an average price of $24.56, for a total transaction of $119,263.36. Following the sale, the director owned 3,506 shares of the company’s stock, valued at $86,107.36. This trade represents a 58.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 3.30% of the company’s stock.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.